Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07822373) titled 'A Phase 2 Study Evaluating Bladder Preservation With Enfortumab Vedotin Plus Pembrolizumab in Patients With Muscle-Invasive Urothelial Cancer' on Sept. 10.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: University of Utah
Condition:
Muscle-invasive Bladder Urothelial Carcinoma
Intervention:
Drug: Enfortumab vedotin
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: November 2026
Target Sample Size: 25
Countries of Recruitment:
United States
To know ...